This is an old revision of this page, as edited by Leyo (talk | contribs) at 06:39, 19 January 2015 (Protected 4-Methylamphetamine: Edit warring / content dispute ( (expires 06:39, 2 February 2015 (UTC)))). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 06:39, 19 January 2015 by Leyo (talk | contribs) (Protected 4-Methylamphetamine: Edit warring / content dispute ( (expires 06:39, 2 February 2015 (UTC))))(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compoundFile:4-methylamphetamine.png | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C10H15N |
Molar mass | 149.23 g/mol g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
4-Methylamphetamine (4-MA; PAL-313; Aptrol; p-TAP) is a stimulant and anorectic drug of the phenethylamine and amphetamine chemical classes.
In vitro, it acts as a potent and balanced serotonin, norepinephrine, and dopamine releasing agent with Ki affinity values of 53.4nM, 22.2nM, and 44.1nM at the serotonin, norepinephrine, and dopamine transporters, respectively. However, more recent in vivo studies that involved performing microdialysis on rats showed a different trend. These studies showed that 4-methylamphetamine is much more potent at elevating serotonin (~18 x baseline) relative to dopamine (~5 x baseline). The authors speculated that this is because 5-HT release dampens DA release through some mechanism. For example, it was suggested that a possible cause for this could be activation of 5HT2C receptors since this is known to inhibit DA release. In addition there are alternative explanations such as 5-HT release then going on to encourage GABA release, which has an inhibitory effect on DA neurons.
4-MA was investigated as an appetite suppressant in 1952 and was even given a trade name, Aptrol, but development was apparently never completed. More recently it has been reported as a novel designer drug.
In animal studies, 4-MA was shown to have the lowest rate of self-administration out of a range of similar drugs tested (the others being 3-methylamphetamine, 4-fluoroamphetamine, and 3-fluoroamphetamine), likely as a result of having the highest potency for releasing serotonin relative to dopamine.
See also
- 1-(4-Methylphenyl)-2-aminobutane
- 2-Methylamphetamine
- 3-Methylamphetamine
- 4-Methyl-N-methylamphetamine
- 4-Methyl-N-methylcathinone
- 3-Methoxy-4-methylamphetamine
- 3,4-Dimethylamphetamine
References
- Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 15677348, please use {{cite journal}} with
|pmid=15677348
instead. - Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 20557570, please use {{cite journal}} with
|pmid=20557570
instead. - Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 14890975 , please use {{cite journal}} with
|pmid=14890975
instead. - Wee, S; Anderson, KG; Baumann, MH; Rothman, RB; Blough, BE; Woolverton, WL (2005). "Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs". The Journal of Pharmacology and Experimental Therapeutics. 313 (2): 848–54. doi:10.1124/jpet.104.080101. PMID 15677348.
- Baumann, MH; Clark, RD; Woolverton, WL; Wee, S; Blough, BE; Rothman, RB. (Apr 2011). "In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat". Journal of Pharmacology and Experimental Therapeutics. 337 (1): 218–25. doi:10.1124/jpet.110.176271. PMC 3063744. PMID 21228061.
Phenethylamines | |
---|---|
Phenethylamines |
|
Amphetamines |
|
Phentermines |
|
Cathinones |
|
Phenylisobutylamines | |
Phenylalkylpyrrolidines | |
Catecholamines (and close relatives) |
|
Miscellaneous |
|